Analysis of the Enteric Nervous System Using Colonic Biopsies (ColoBioParker)

Nantes University Hospital (NUH)

Status

Completed

Conditions

Multiple System Atrophy

Parkinson's Disease

Progressive Supranuclear Palsy

Treatments

Procedure: colonoscopy or rectosigmoidoscopy

Study type

Interventional

Funder types

Other

Identifiers

NCT01353183

10/4-U

ID RCB 2010-A00632-37 (Registry Identifier)

Details and patient eligibility

About

The aim of this project is to develop an original biomarker for Parkinson's disease (PD) and other parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy) based upon the detection of pathological alpha-synuclein species in routine colonoscopic biopsies.

Enrollment

34 patients

Sex

All

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients

Patients aged 50-80 year old, both genders
Parkinson's disease patients
Multiple system atrophy patients
Progressive supranuclear palsy patients
Controls: patient at risk of colic cancer for whom a colonoscopy is required
Patients who signed the informed consent

Controls

Patients aged 50 to 80 year-old for whom a rectosigmoidoscopy or a colonoscopy is required for colorectal screening
Patients who signed the informed consent
Health care beneficiary

Exclusion criteria

Patients

Colonic disorder (except non-complicated diverticular disease)
Other neurological disorder than parkinsonism
Patients treated with either platelet antiaggregants, anticoagulants or with a known coagulation disorder
Patients with a cognitive impairment that preclude them from understanding the informed consent
Patients placed under legal guardianship

Controls

Neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease or other dementia, amyotrophic lateral sclerosis...
Functional bowel disorder such as irritable bowel syndrome
Patients with a cognitive impairment that preclude them from understanding the informed consent